Edition:
United States

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

25.68CHF
20 Jul 2018
Change (% chg)

CHF0.06 (+0.23%)
Prev Close
CHF25.62
Open
CHF25.78
Day's High
CHF26.00
Day's Low
CHF25.62
Volume
218,913
Avg. Vol
321,528
52-wk High
CHF30.70
52-wk Low
CHF16.05

Select another date:

Wed, Jul 11 2018

UPDATE 1-Idorsia CEO accelerates fundraising with 505 mln Sfr deal

ZURICH, July 11 Swiss drugmaker Idorsia's Chief Executive Jean-Paul Clozel on Wednesday accelerated fundraising for his drug pipeline, reaping around 505 million Swiss francs ($509 million) by selling new shares and convertible bonds.

Idorsia raises 505 mln Sfr from shares, bonds to fund pipeline

ZURICH, July 11 Swiss drugmaker Idorsia's Chief Executive Jean-Paul Clozel on Wednesday accelerated fundraising for his drug pipeline, reaping around 505 million Swiss francs ($509 million) by selling new shares and convertible bonds.

BRIEF-Idorsia Launches Offering Of New Shares And Convertible Bonds

* IDORSIA LAUNCHES THE OFFERING OF NEW SHARES IN COMBINATION WITH THE OFFERING OF CONVERTIBLE BONDS TO FUND THE DEVELOPMENT OF ITS ADVANCING PIPELINE

After split from Actelion, Idorsia CEO plans to raise more cash in 2019

ALLSCHWIL, Switzerland Swiss biotech Idorsia , spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson , will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters.

BRIEF-Idorsia Initiates Phase 3 Registration Program With Nemorexant For Treatment Of Insomnia

* INITIATES A PHASE 3 REGISTRATION PROGRAM WITH NEMOREXANT (ACT-541468) FOR TREATMENT OF INSOMNIA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Idorsia Starts Phase 3 Registration Study To Assess Lucerastat As Potential New Treatment Option For Patients With Fabry Disease

* IDORSIA INITIATES MODIFY, A PHASE 3 REGISTRATION STUDY TO ASSESS LUCERASTAT AS A POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WITH FABRY DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Idorsia: US GAAP Oper Loss Of CHF 74 Mln In Q1 2018

* IDORSIA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2018

BRIEF-Idorsia FY US GAAP Loss Of CHF 8 Million

* US GAAP OPERATING RESULTS 2017: YTD LOSS OF CHF 8 MILLION; Q4 PROFIT OF CHF 71 MILLION

Select another date: